clinical trial · NCT05604170
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Tuberous Sclerosis ComplexGanaxolone
brief summary
This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001
started
May 16, 2022
primary completion
Apr 2, 2025
completion
Apr 2, 2025
last updated
Oct 1, 2025
official title
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol